SCHEMBL4345291

SCHEMBL4345291

CC(c1cc(F)c(F)c(F)c1)N1CCOC(O)C1=O

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.39
ENPP2 Q13822 1/20 0.30
LPAR1 Q92633 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337347 0.73 HSD11B1 (0.36) HSD11B1
SCHEMBL4328180 0.69 TACR1 (0.33)
SCHEMBL8153816 0.68 HSD11B1 (0.38) HSD11B1
SCHEMBL24677739 0.62
SCHEMBL8038060 0.61 HSD11B1 (0.51) HSD11B1
SCHEMBL12913818 0.59 PER2 (0.34) HSD11B1ENPP2
SCHEMBL4326221 0.59 HSD11B1 (0.46) HSD11B1
SCHEMBL14035487 0.59 CHRM2 (0.44)
SCHEMBL4088740 0.59 HSD11B1 (0.48) HSD11B1
SCHEMBL19651819 0.57 MAPT (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618960-B2 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-17 US disclosed
EP-1953154-A1 MORPHOLINE TYPE CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2008-08-06 EP disclosed
US-20070117798-A1 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117798-A1 Morpholine type cinnamide compound MLX, XDH, NOX4 HSD11B1 985/4885ENPP2 3010/4885LPAR1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.